Camurus AB
STO:CAMX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
439.4
714.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CAMX stock under the Base Case scenario is 929.16 SEK. Compared to the current market price of 559.5 SEK, Camurus AB is Undervalued by 40%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Camurus AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CAMX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Camurus AB
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Camurus AB
Balance Sheet Decomposition
Camurus AB
Current Assets | 3.3B |
Cash & Short-Term Investments | 2.8B |
Receivables | 346.9m |
Other Current Assets | 237.3m |
Non-Current Assets | 231.1m |
PP&E | 40.2m |
Intangibles | 22.3m |
Other Non-Current Assets | 168.6m |
Current Liabilities | 403.3m |
Accounts Payable | 78.4m |
Accrued Liabilities | 251.8m |
Other Current Liabilities | 73.2m |
Non-Current Liabilities | 50.9m |
Long-Term Debt | 8.5m |
Other Non-Current Liabilities | 42.4m |
Earnings Waterfall
Camurus AB
Revenue
|
1.7B
SEK
|
Cost of Revenue
|
-128.8m
SEK
|
Gross Profit
|
1.6B
SEK
|
Operating Expenses
|
-1.3B
SEK
|
Operating Income
|
274.6m
SEK
|
Other Expenses
|
-8.4m
SEK
|
Net Income
|
266.2m
SEK
|
Free Cash Flow Analysis
Camurus AB
SEK | |
Free Cash Flow | SEK |
In Q3 2024, Camurus reported a strong revenue growth of 38% year-on-year to SEK 480 million, largely driven by a 22% increase in Buvidal sales, totaling SEK 421 million. Profit before tax surged 125% to SEK 165 million. The company has raised its annual revenue forecast to SEK 1.81-1.88 billion from SEK 1.73-1.84 billion and profit guidance to SEK 450-510 million, up from SEK 330-450 million. While experiencing a Complete Response Letter from the FDA regarding manufacturing, Camurus remains on track with its long-term goals as its cash position strengthens to SEK 2.75 billion, indicating robust operational health.
What is Earnings Call?
CAMX Profitability Score
Profitability Due Diligence
Camurus AB's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Camurus AB's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
CAMX Solvency Score
Solvency Due Diligence
Camurus AB's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Camurus AB's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CAMX Price Targets Summary
Camurus AB
According to Wall Street analysts, the average 1-year price target for CAMX is 717.91 SEK with a low forecast of 515.1 SEK and a high forecast of 806.4 SEK.
Dividends
Current shareholder yield for CAMX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CAMX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Camurus AB operates as a research based pharmaceutical company. The company is headquartered in Lund, Skane and currently employs 148 full-time employees. The company went IPO on 2015-12-03. The firm has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
Officers
The intrinsic value of one CAMX stock under the Base Case scenario is 929.16 SEK.
Compared to the current market price of 559.5 SEK, Camurus AB is Undervalued by 40%.